ripertamab

Phase 3Monoclonal antibody

ripertamab is one of 91 small molecule programs targeting Chronic Inflammatory Demyelinating Polyneuropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Inflammatory Demyelinating PolyneuropathyActive, not recruiting

Nephrotic SyndromeActive, not recruiting

Myasthenia GravisActive, not recruiting

Chronic Inflammatory Demyelinating PolyneuropathyPhase 3

Active, not recruiting

Nephrotic SyndromePreclinical

Active, not recruiting

Myasthenia GravisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

102 competitors in Myasthenia Gravis

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

7 2

Ultomiris

AstraZeneca

Phase 3

5 3

Vyvgart

Argenx

Phase 3

17 4

Zilbrysq

UCB

Phase 3

4 5

Cellcept

Roche

Phase 3

4 6

Soliris

AstraZeneca

Phase 3

4 7

Fabhalta

Johnson & Johnson

Phase 3

3 8

ENSPRYNG

Roche

Phase 3

1 9

Rhapsido

Novartis

Phase 3

1 10

Arava

Sanofi

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Not yet recruiting

Myasthenia Gravis

NCT07372807

Phase 3Not yet recruiting

Chronic Inflammatory Demyelinating Polyneuropathy

NCT06858722

Q1 2028

N/ANot yet recruiting

Nephrotic Syndrome

NCT07388810

Clinical

Trials by Indication[1]

Nephrotic Syndrome1 trial

Study of Ripertamab in Children With Frequent Relapses or Steroid-Dependent Nephrotic Syndrome

Not yet recruiting·MMao Jianhua·N/A·NCT07388810·312 enrolled

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

Ripertamab for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy

Not yet recruiting·ZZhongming Qiu·Phase 3·NCT06858722·175 enrolled

Myasthenia Gravis1 trial

Ripertamab for the Treatment of Myasthenia Gravis

Not yet recruiting·ZZhongming Qiu·Phase 1/2·NCT07372807·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ripertamab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ripertamab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ripertamab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhongming Qiu company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: ZZhongming Qiu

ripertamab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2028

Trials by Indication[1]

Nephrotic Syndrome1 trial

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

Myasthenia Gravis1 trial

References

Drug Info

Quick Facts

Related News